Article

B&L announces eyeonics and CrystalGenomics deals, new leader

Rochester, NY-Bausch & Lomb (B&L) has acquired eyeonics inc., has announced a joint research and development pact with CrystalGenomics  (CG) Inc., and has named Gerald M. Ostrov as chairman and chief executive officer (CEO).

Rochester, NY-Bausch & Lomb (B&L) has acquired eyeonics inc., has announced a joint research and development pact with CrystalGenomics  (CG) Inc., and has named Gerald M. Ostrov as chairman and chief executive officer (CEO).

The eyeonics’ Aliso Viejo, CA-based operations now are part of B&L’s surgical business, the U.S. portion of which is being led by J. Andy Corley, eyeonics’ co-founder, chairman, and CEO. The company, founded in 1998, developed and markets the only FDA-approved accommodating IOL (crystalens), which, according to B&L, has been implanted in more than 95,000 eyes worldwide. The FDA approved the lens in 2003.

“This represents our first acquisition since Bausch & Lomb became a private company in a transaction led by Warburg Pincus,” said Ronald L. Zarrella, B&L chairman and CEO at the time of the announcement. “This acquisition immediately places [B&L] into the rapidly expanding premium IOL market.”

In 2007, eyeonics generated revenues of approximately $34 million, an increase of 100% over prior-year revenues. Its accommodating IOL is estimated to represent approximately 30% of the presbyopic IOL market in the United States.

“We expect that this transaction will lead to accelerated adoption of the [accommodating] IOL,” said Corley.

Financial terms of the eyeonics transaction were not disclosed.

In other news, B&L and CG announced plans to join efforts to study potential new treatments for inflammatory ophthalmic diseases. CG, of Seoul, South Korea, will provide new pharmaceutical candidate compounds, and B&L will develop product formulations, conduct pre-clinical and clinical studies, and bring the products to market.

“Our collaborations with overseas bio and pharmaceutical firms leverage the strengths of [CG] and our partners-a win-win situation,” said Joong Myung Cho, CG president and CEO.

“This collaboration has the potential to extend our leadership in anti-inflammatory ophthalmic pharmaceuticals, especially with [CG’s] unique three-dimensional, structure-based optimization technology for compound discovery,” said Praveen Tyle, PhD, chief scientific officer for B&L.

Financial terms of the agreement were not disclosed.

B&L announced Ostrov as the company’s new chairman and CEO effective Jan. 23. Most recently, he was group chairman, worldwide vision care, for Johnson & Johnson (J&J), where he led the company’s global vision-care businesses from 1998 to 2006. His career also has included positions as president of Ciba Consumer Pharmaceuticals, president of J&J’s personal products business, and chairman of J&J’s North American consumer and personal-care businesses.

Zarrella, who had been chairman and CEO since 2001, will retire in March and serve as chairman emeritus.

B&L projects fourth-quarter 2007 net sales of $654 million to $660 million, compared with $598 million in the same period in 2006. For all of 2007, B&L projects net sales of approximately $2.5 billion compared with about $2.3 billion in 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.